Andamertinib

Andamertinib
Clinical data
Other namesGTPL13732, PLB1004
ATC code
  • None
Legal status
Legal status
  • Rx in China
Identifiers
  • N-[4-Methoxy-2-[4-(3-methoxyazetidin-1-yl)piperidin-1-yl]-5-[[6-(1-methylindazol-5-yl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide
CAS Number
PubChem CID
IUPHAR/BPS
UNII
Chemical and physical data
FormulaC31H36N8O3
Molar mass568.682 g·mol−1
3D model (JSmol)
  • CN1C2=C(C=C(C=C2)C3=CC(=NC=N3)NC4=C(C=C(C(=C4)NC(=O)C=C)N5CCC(CC5)N6CC(C6)OC)OC)C=N1
  • InChI=1S/C31H36N8O3/c1-5-31(40)36-25-13-26(29(42-4)15-28(25)38-10-8-22(9-11-38)39-17-23(18-39)41-3)35-30-14-24(32-19-33-30)20-6-7-27-21(12-20)16-34-37(27)2/h5-7,12-16,19,22-23H,1,8-11,17-18H2,2-4H3,(H,36,40)(H,32,33,35)
  • Key:KKPCZGCBAIJCOU-UHFFFAOYSA-N

Andamertinib is pharmaceutical drug developed by Avistone Biotechnology for the treatment of non-small-cell lung cancer (NSCLC). It is an epidermal growth factor receptor (EGFR) antagonist. Andamertinib is an irreversible EGFR inhibitor designed to target EGFR with exon 20 insertion mutations.

Use

In April 2026, andamertinib received conditional approval in China for adult patients with locally advanced or metastatic NSCLC who have experienced disease progression during or following platinum-based chemotherapy, or who are intolerant to platinum-based chemotherapy, and who have been confirmed by testing to have an EGFR exon 20 insertion mutation.

Clinical trials

The following clinical trials are evaluating andamertinib for treating NSCLC: